- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Active Surveillance Might Work for Most With Prostate Cancer
A recent study published in European Urology highlights quality-of-life benefits with active surveillance in men with prostate cancer.
Men who opt for surveillance of their tend to have physical and mental wellbeing equal to or better than men who opt for immediate treatment, a new analysis suggests.
"The men in our study did not appear to suffer from any major negative psychological impacts, including and depression," said Dr. Lara Bellardita, the study's lead author from the IRCCS Foundation's National Cancer Institute in Milan, Italy.
Many men with prostate cancer will never need treatment for it, while about a third will go on to get treated after an average of two to three years of surveillance, said Dr. Marc A. Dall'Era, who wasn't involved with the new study but is a urologist at the University of California, Davis.
Link to the article in Medscape: http://bit.ly/1HuXGXs
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Texas Oncology to Roll Out Canopy for ePROs After Head-to-Head Pilot
March 18th 2025Debra Patt, MD, PhD, MBA, executive vice president of Public Policy and Strategy for Texas Oncology, said the practice received positive feedback from nurses and patients during a pilot that concluded in February.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
